Edward Vranic, CFA
Contributor since: 2012
Company: Edward Vranic
Latest Articles
The Market Is Rightfully Nervous Over MiMedx's Latest Bad News
Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target
MiMedx: Taking A Deeper Look At The Stability Transaction
MiMedx Sinks After Conference Call, Marc Cohodes' Throwdown
MiMedx: Do The Numbers Support Channel Stuffing Accusations?
Short Sell Target: 7 Reasons To Expect Shutterfly To Drop Significantly In Price
Kodak And Overstock.Com: The Perfect Partnership To Take Advantage Of The Cryptohype
Selectcoin: Don't Invest In Bitcoin; Invest In Bitcoin Infrastructure
Nova Lifestyle Has A Fair Value Of $5 As Company Addresses Concerns
Urban FT Offers To Buy Digiliti: Is This A Creative Marketing Ploy?
Applied Optoelectronics' Road To $105: A Stock Buyback And A Short Squeeze
Prepare For More Dilution Of Inovio Pharmaceuticals
LightPath Technologies: Undervalued And Overlooked Small-Cap Player In A Hot Optical Components Industry
Real Goods Solar Is About To Collapse Under A Mountain Of Toxic Financing
GW Pharmaceuticals Executive Sells Shares Conveniently One Week After Buyout Rumor Pop
GW Pharmaceuticals' Buyout Rumor Appears Suspect: Liquidity Event For Recent Secondary?
Why Fossil Is On The Verge Of Collapse
Fossil: The Worst Is Yet To Come
Anavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price
A Sarepta-Like Run Might Be Coming On PTC Therapeutics
SunEdison's Audit Finds No Evidence Of Fraud, But Bond Traders Are Largely Unimpressed
Baytex Energy Is Due For A Drop As Noteholders Sell At Junk Bond Yields
SunEdison's Recent Bond Trading Indicates A Slight Recovery In Its Fortunes
Cree's Growth Phase Appears Dead, A Fair Value For The Stock Is $20
VirtualScopics Shareholders Should Refuse To Tender Their Shares To BioTelemetry
PTC Therapeutics: Discounted To No Enterprise Value Despite Current Sales
PTC Therapeutics Has Value At $8
Buyout Candidate YRC Worldwide: An Opportunity That Should Not Be Passed Up
VirtualScopics: A Well-Managed, Small Float Stock On The Edges Of Biotech
The Systematic Erosion Of The Retirement Savings Of Canadians
A Former Bear Converted: A Market Overreaction Regarding GoPro?
A Short Squeeze May Be Coming On Amira Nature Foods As It Fights Fraud Allegations In Court